Compounded vs brand semaglutide (Wegovy): what actually differs
Compounded semaglutide and brand Wegovy contain the same active molecule but differ in FDA status, cost, and formulation. Here's an honest comparison of the trade-offs.
The core differences
Both deliver semaglutide, but the regulatory and practical differences are significant. Brand Wegovy has been through FDA review for safety, efficacy, and manufacturing consistency. Compounded versions are prepared by licensed 503A/503B pharmacies and are legal, but not FDA-approved — meaning quality, formulation, and dosing can vary by pharmacy.
The published weight-loss statistics (STEP 1's ~14.9%) come from trials of the brand product, not compounded formulations.
It's worth stressing that 'not FDA-approved' is not the same as 'illegal' or 'ineffective' — compounded medications are a long-standing, regulated part of US pharmacy. The distinction is about the level of manufacturing oversight and the fact that trial data was generated with the brand product.
Side-by-side
The table summarizes the practical differences. The right choice depends on whether FDA-approved status, cost, or convenience matters most to you — and on what your insurance will cover.
Treat these points as a well-evidenced starting framework rather than a personal recommendation. The optimal path depends on your history, tolerability, and goals, which a clinician can weigh with you directly.
| Feature | Brand Wegovy | Compounded semaglutide |
|---|---|---|
| FDA-approved | Yes | No (legally compounded) |
| Monthly cost (cash) | ~$1,349 | $79–$289 |
| Formulation | Prefilled pen | Multi-dose vial + syringe |
| Insurance | Sometimes covered | Rarely covered |
| Trial data applies | Directly | Not directly |
How to choose
If you have insurance coverage or a manufacturer savings card, brand Wegovy may be affordable and gives you the FDA-approved product. If you're paying cash and coverage is denied, compounded is the accessible route — but choose a program that names a verifiable pharmacy and provides clinician oversight.
As of 2026 the FDA has declared the semaglutide shortage resolved and warned against misleading marketing of compounded GLP-1 products, so scrutinize any provider that implies a compounded product is a standard substitute for the brand.
This is education, not medical advice. The best choice varies with your health profile, medications, and what you are optimizing for, so bring these details to a licensed clinician to personalize the plan.
The bottom line
Compounded and brand semaglutide share a molecule but not a regulatory status. If coverage makes brand Wegovy affordable, it's the trial-tested choice; if you're paying cash, compounded is the accessible route — provided you pick a transparent, clinician-supported program.
A reasonable middle path many patients take: start the insurance conversation for brand Wegovy first, and treat compounded as the fallback if coverage is denied. That sequence captures the FDA-approved option when it's affordable and the accessible one when it isn't.
Across the trials, the biggest results belonged to patients who treated semaglutide as one part of a durable routine — effective dose reached and held, protein and resistance training in place, and follow-up maintained. Because the benefits depend on continuation, the sustainability of your program (its cost, support, and convenience) is as decisive as the medication itself.
How we verify pricing & evidence
The prices here come from the RangeYourself independent telehealth price index, human-verified against each provider's public pricing page during July 1–3, 2026 (CC-BY-4.0, attributed). Efficacy and safety figures are drawn from the STEP (semaglutide) and SURMOUNT (tirzepatide) pivotal-trial programs and peer-reviewed outcome studies. Prices change, so confirm the current rate at your dose before deciding — and note that compounded GLP-1s are not FDA-approved and aren't identical to the brand drugs studied in those trials.
Frequently asked questions
It contains the same active molecule but is not FDA-approved and may differ in formulation, concentration, and inactive ingredients. Brand Wegovy is the FDA-approved, trial-tested product.
Compounded products avoid brand pricing and are prepared by pharmacies rather than a single manufacturer. Price differences reflect overhead and margins more than the molecule itself.
Yes, when prepared by a licensed 503A or 503B pharmacy for a patient with a valid prescription. It is not FDA-approved, which is a separate matter from legality.
Brand Wegovy is sometimes covered (often with prior authorization); compounded semaglutide is rarely covered. Check your plan's formulary.
Key takeaways
- Both contain semaglutide, but only brand Wegovy is FDA-approved and trial-tested.
- Compounded costs $79–$289/month cash-pay versus ~$1,349 for brand Wegovy.
- Published weight-loss statistics come from brand trials, not compounded formulations.
- Choose compounded providers that name a verifiable 503A/503B pharmacy and provide clinician oversight.